These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 1812946)

  • 21. Antibody responses of chimpanzees immunized with synthetic peptides corresponding to full-length V3 hypervariable loops of HIV-1 envelope glycoproteins.
    Neurath AR; Jiang S; Strick N; Kolbe H; Kieny MP; Muchmore E; Girard M
    AIDS Res Hum Retroviruses; 1991 Oct; 7(10):813-23. PubMed ID: 1720628
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells.
    Fultz PN; Nara P; Barre-Sinoussi F; Chaput A; Greenberg ML; Muchmore E; Kieny MP; Girard M
    Science; 1992 Jun; 256(5064):1687-90. PubMed ID: 1609280
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group protocol 185.
    Stiehm ER; Lambert JS; Mofenson LM; Bethel J; Whitehouse J; Nugent R; Moye J; Glenn Fowler M; Mathieson BJ; Reichelderfer P; Nemo GJ; Korelitz J; Meyer WA; Sapan CV; Jimenez E; Gandia J; Scott G; O'Sullivan MJ; Kovacs A; Stek A; Shearer WT; Hammill H
    J Infect Dis; 1999 Mar; 179(3):567-75. PubMed ID: 9952362
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elimination of HIV-1 infection by treatment with a doxorubicin-conjugated anti-envelope antibody.
    Johansson S; Goldenberg DM; Griffiths GL; Wahren B; Hinkula J
    AIDS; 2006 Oct; 20(15):1911-5. PubMed ID: 16988511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Passive immunization with human neutralizing monoclonal antibodies against HIV-1 in macaque models: experimental approaches.
    Ruprecht RM
    Methods Mol Biol; 2009; 525():559-66, xiv. PubMed ID: 19252837
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
    Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M
    J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. Pediatric AIDS Clinical Trials Group Protocol 185 Pharmacokinetic Study Group.
    Lambert JS; Mofenson LM; Fletcher CV; Moye J; Stiehm ER; Meyer WA; Nemo GJ; Mathieson BJ; Hirsch G; Sapan CV; Cummins LM; Jimenez E; O'Neill E; Kovacs A; Stek A
    J Infect Dis; 1997 Feb; 175(2):283-91. PubMed ID: 9203648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of nonprotective vaccination on antibody response to subsequent human immunodeficiency virus infection.
    Pincus SH; Messer KG; Hu SL
    J Clin Invest; 1994 Jan; 93(1):140-6. PubMed ID: 8282780
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Model for competition from self during passive immunization, with application to broadly neutralizing antibodies for HIV.
    Ali Tabei SM; Li Y; Weigert M; Dinner AR
    Vaccine; 2012 Jan; 30(3):607-13. PubMed ID: 22119591
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The prevention of maternal-fetal HIV-1 infection through passive antibody products (HIVIG) and active immunization (AIDS vaccines).
    Lambert JS
    Pediatr AIDS HIV Infect; 1995 Oct; 6(5):300-2. PubMed ID: 11361396
    [No Abstract]   [Full Text] [Related]  

  • 31. Cultural feasibility studies in preparation for clinical trials to reduce maternal-infant HIV transmission in Haiti.
    Coreil J; Losikoff P; Pincu R; Mayard G; Ruff AJ; Hausler HP; Desormeau J; Davis H; Boulos R; Halsey NA
    AIDS Educ Prev; 1998 Feb; 10(1):46-62. PubMed ID: 9505098
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques.
    Miyake A; Akagi T; Enose Y; Ueno M; Kawamura M; Horiuchi R; Hiraishi K; Adachi M; Serizawa T; Narayan O; Akashi M; Baba M; Hayami M
    J Med Virol; 2004 Jul; 73(3):368-77. PubMed ID: 15170630
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV vaccine development: lessons learned to date.
    Putney SD
    Biotechnol Ther; 1991; 2(1-2):1-7. PubMed ID: 1726960
    [No Abstract]   [Full Text] [Related]  

  • 34. Characterization of a vaccinia-derived recombinant HIV-1 gp160 candidate vaccine and its immunogenicity in chimpanzees.
    Barrett N; Eder G; Dorner F
    Biotechnol Ther; 1991; 2(1-2):91-106. PubMed ID: 1845126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human antibodies that neutralize primary human immunodeficiency virus type 1 in vitro do not provide protection in an in vivo model.
    Schutten M; Tenner-Racz K; Racz P; van Bekkum DW; Osterhaus AD
    J Gen Virol; 1996 Aug; 77 ( Pt 8)():1667-75. PubMed ID: 8760413
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infection.
    Bunnik EM; van Gils MJ; Lobbrecht MS; Pisas L; van Nuenen AC; Schuitemaker H
    Virology; 2009 Aug; 390(2):348-55. PubMed ID: 19539340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Methods for analysis of biologically functional antibodies to the HIV-1 gp120 principal neutralizing domain.
    Devash Y; Rusche JR; Nara PL
    Biotechnol Ther; 1991; 2(1-2):49-62. PubMed ID: 1845124
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Passive immunity in the prevention of maternal-fetal transmission of human immunodeficiency virus infection.
    Lambert JS; Stiehm ER
    Ann N Y Acad Sci; 1993 Oct; 693():186-93. PubMed ID: 7980738
    [No Abstract]   [Full Text] [Related]  

  • 39. Combination antibody treatment controls HIV infection in phase 1 trial.
    Harper KN
    AIDS; 2019 Mar; 33(3):N3-N4. PubMed ID: 30585848
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical trials of HIVIG.
    Moore JP
    J Infect Dis; 1998 Aug; 178(2):597-9. PubMed ID: 9697754
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.